C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy

Table 1—

Neurophysiological and neurological results at baseline and change from baseline to 6 months of treatment

Baseline Change from baseline
Placebo Active combined C-peptide
Low dose High dose
n 139 47 92 53 30
Neurographic variables
    SCVp (m/s) 35.4 ± 0.31 0.24 ± 0.27 0.48 ± 0.19† 0.38 ± 0.27 0.63 ± 0.26*
    SCVi (m/s) 44.2 ± 0.41 0.75 ± 0.38 0.93 ± 0.29† 0.77 ± 0.43* 1.14 ± 0.36†
    MCV (m/s) 40.0 ± 0.41* −0.53 ± 0.22* −0.38 ± 0.15* −0.25 ± 0.19 −0.57 ± 0.24*
VPT
    z-VPT foot 1.9 ± 0.12 0.03 ± 0.13 −0.09 ± 0.07 −0.07 ± 0.09 −0.12 ± 0.11
    z-VPT lower leg 0.6 ± 0.10 −0.09 ± 0.08 −0.19 ± 0.06† −0.18 ± 0.06* −0.22 ± 0.13‡
Neurological examination
    NIA score (points) 18.0 ± 0.86 −0.9 ± 0.94 −2.2 ± 0.78† −1.7 ± 0.97 −2.7 ± 1.31*

  • Data are means ± SE. Improvements for VPTs and the neurological assessment are indicated as negative differences. z indicates that the variable is expressed as a z-score, i.e., deviation from the corresponding reference value expressed in SD.

  • *

    ↵* P < 0.05,

  • †

    ↵† P < 0.01, and

  • ‡

    ↵‡ P = 0.057 for differences within groups compared with baseline.

This Article

  1. Diabetes Care January 2007 vol. 30 no. 1 71-76
  1. AbstractFree
  2. Full Text
  3. Full Text (PDF)

Current Issue

  1. December 2009, 32 (12)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care